Should the use of a brachytherapy boost affect the duration or use of ADT in intermediate or high risk prostate cancer?
Does the 1 year of ADT used in the ASCENDE-RT trial present a new option of the standard of care in timing ADT when combined with brachtherapy boost?
Community PollStarted
What duration of hormonal therapy would you prescribe for a man with T3, Gleason 8 prostate cancer, PSA 15, who receives a brachytherapy boost?
80 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · University of Chicago
Answered on
We traditionally think of 4-6 mo ADT for intermediate risk, and 18-36 mo ADT for high risk men treated with EBRT (whether dose escalated or not). For high risk men in our practice, I have usually recommended 28 mo (from RTOG 9202) ADT as a standard. I do think it is fair to consider a course <28 mo ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Rutgers Cancer Institute of New Jersey
Answered on
@Dr. First Last has summarized the issues well. My overall sense is the main benefit of ADT in combination with RT is on local disease. So, in the setting of a brachy boost, I generally use NO ADT in intermediate risk patients as well as the low end of high risk (e.g. favorable factors aside from Gl...
Join for free or sign in to see the full answer